The current status of drug repositioning and vaccine developments for the COVID-19 pandemic

31Citations
Citations of this article
191Readers
Mendeley users who have this article in their library.

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.

Cite

CITATION STYLE

APA

Won, J. H., & Lee, H. (2020, December 2). The current status of drug repositioning and vaccine developments for the COVID-19 pandemic. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms21249775

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free